BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET

Company Participants

John Bluth - SVP, IR and Corporate Communications

Jon Stonehouse - Chief Executive Officer

Anthony Doyle - Chief Financial Officer

Charlie Gayer - Chief Commercial Officer

Helen Thackray - Chief R&D Officer

Conference Call Participants

Ken Cacciatore - Cowen and Company

Chris Raymond - Piper Sandler

Daniel Wolle - JPMorgan

Joe Spak - RBC Capital

Jon Wolleben - JMP Securities

Gena Wang - Barclays

Justin Kim - Oppenheimer & Company

Tazeen Ahmad - Bank of America

Rohit Bhasin - Needham & Company

Maury Raycroft - Jefferies

Operator

Hello, and welcome to the BioCryst Third Quarter 2022 Earnings Conference Call. My name is Michelle and I will be your operator for today's conference. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session [Operator Instructions] As a reminder, the conference is being recorded.

I will now turn the call over to Mr. John Bluth with BioCryst. Sir, you may begin.

John Bluth

Thanks Michelle. Good morning, and welcome to BioCryst's third quarter 2022 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we will answer your questions.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements.

These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements.

For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website.

I'd now like to turn the call over to Jon Stonehouse.

Jon Stonehouse

Thanks John. We continue to see steady progress with the ORLADEYO launch, and underlying growth trends remain strong. New patient starts are consistent with previous quarters, discontinuations appear to have stabilized, and we are investing more to keep this momentum going.

Based on our expectations for continued growth in Q4, we plan to exit 2022, having more than doubled sales from the great start we had last year, and we'll be a quarter of the way to our expected peak of $1 billion globally in just the second year of launch.